A Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for Head and Neck Squamous Cell Carcinoma
Latest Information Update: 30 May 2025
At a glance
- Drugs Cemiplimab (Primary) ; Cetuximab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
Most Recent Events
- 07 Mar 2025 New trial record